表紙
市場調查報告書

整合素β1:開發中產品分析

Integrin Beta 1 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 367836
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
整合素β1:開發中產品分析 Integrin Beta 1 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 65 Pages
簡介

本報告提供以整合素β1為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

整合素β1 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥開發企業

  • Clanotech AB
  • Valeant Pharmaceuticals International, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2133TDB

Summary

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Integrin beta-1 also known as CD29 is a protein encoded by the ITGB1 gene. It is involved in up-regulation of the activity of kinases such as PKC via binding to KRT1. It plays a mechanistic adhesive role during telophase. Integrin alpha-3/beta-1 provides a docking site for FAP at invadopodia plasma membranes in a collagen-dependent manner and participates in the adhesion, formation of invadopodia and matrix degradation processes, promoting cell invasion.

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) pipeline Target constitutes close to 16 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 3, 8 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Oncology, Ophthalmology, Immunology, Cardiovascular, Infectious Disease, Musculoskeletal Disorders and Respiratory which include indications Primary Sclerosing Cholangitis, Liver Fibrosis, Rheumatoid Arthritis, Wet (Neovascular / Exudative) Macular Degeneration, Arterial Thrombosis, Breast Cancer, Ebolavirus Infections (Ebola Hemorrhagic Fever), Fibrosis, Idiopathic Pulmonary Fibrosis, Keratoconjunctivitis Sicca (Dry Eye), Metastatic Lung Cancer, Metastatic Melanoma, Non-Alcoholic Steatohepatitis (NASH), Prostate Cancer, Solid Tumor and Triple-Negative Breast Cancer (TNBC).

The latest report Integrin Beta 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1)
  • The report reviews Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Overview
  • Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Companies Involved in Therapeutics Development
  • 7 Hills Pharma LLC
  • AsclepiX Therapeutics Inc
  • Avipero Ltd
  • AxeroVision Inc
  • Bausch Health Companies Inc
  • Morphic Holding Inc
  • Nodus Therapeutics Inc
  • ODIN Biotech Partners LLC
  • Pliant Therapeutics Inc
  • Tasly Pharmaceutical Group Co Ltd
  • Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Drug Profiles
  • 7HP-349 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Antibody + Small Molecule - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AXR-159 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AXT-108 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • C-16Y - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fusion Protein to Antagonize Integrin Alpha V Beta 3 and Integrin Alpha 5 Beta 1 for Rheumatoid Arthritis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NOD-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PLN-1177 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PLN-1474 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PLN-1561 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PLN-74809 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Protein to Antagonize Alpha5Beta1 Integrin and EGFR for Triple Negative Breast Cancer and Metastatic Lung Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SAN-300 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize Integrin Alpha V and Integrin Beta 1 for Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit Integrin alpha 2 beta 1 for Arterial Thrombosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptides to Antagonize Alpha5Beta1 Integrin for Breast and Prostate Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Dormant Products
  • Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Discontinued Products
  • Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Product Development Milestones
  • Featured News & Press Releases
  • Oct 31, 2019: Pliant Therapeutics to Present Preclinical Data in Primary Sclerosing Cholangitis at The Liver Meeting 2019
  • Oct 15, 2019: Pliant Therapeutics announces publication demonstrating feasibility of positron emission tomography (PET) tracers for imaging fibrosis in patients with idiopathic pulmonary fibrosis
  • Jun 28, 2019: Pliant Therapeutics completes trial of PLN-74809 to treat in IPF
  • Jun 27, 2019: Pliant Therapeutics reports positive results of phase 1b clinical study supporting advancement of PLN-74809 for treatment of Idiopathic Pulmonary Fibrosis
  • Apr 09, 2019: Pliant Therapeutics reports positive results of phase 1 clinical study support advancement of PLN-74809 for idiopathic pulmonary fibrosis
  • Mar 28, 2019: Pliant Therapeutics presents data in human NASH liver tissue at The International Liver Congress 2019 Hosted by the European Association for the Study of the Liver (EASL)
  • Jan 03, 2019: Experimental treatment shows promise against triple-negative breast cancer in mouse study
  • Jan 03, 2019: Pliant Therapeutics initiates phase 1 clinical study of PLN-74809
  • Nov 20, 2018: Pliant Therapeutics receives FDA orphan drug designation for lead program PLN-74809 in primary sclerosing cholangitis
  • Nov 09, 2018: Pliant Therapeutics presents preclinical data in PSC at The Liver Meeting 2018
  • Aug 06, 2018: Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis
  • Jul 24, 2018: 7 Hills Pharma appoints Lionel D. Lewis as chief medical officer
  • Jun 26, 2018: 7 Hills Pharma Announces Scientific Advisory Board Formed With Prominent Immuno-Oncology Experts to Help Advance Novel Integrin Activator Program
  • Jun 19, 2018: 7 Hills Pharma Launches With $2 Million SBIR Grant in Addition to $4 Million in Seed Capital to Pursue Novel Cancer Therapeutics to Promote a Productive Immune Response and Overcome Drug Resistance
  • Dec 23, 2013: Santarus Initiates Phase IIa Study with SAN-300 in Patients with Active Rheumatoid Arthritis
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by 7 Hills Pharma LLC, H2 2019
  • Pipeline by AsclepiX Therapeutics Inc, H2 2019
  • Pipeline by Avipero Ltd, H2 2019
  • Pipeline by AxeroVision Inc, H2 2019
  • Pipeline by Bausch Health Companies Inc, H2 2019
  • Pipeline by Morphic Holding Inc, H2 2019
  • Pipeline by Nodus Therapeutics Inc, H2 2019
  • Pipeline by ODIN Biotech Partners LLC, H2 2019
  • Pipeline by Pliant Therapeutics Inc, H2 2019
  • Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Dormant Products, H2 2019 (Contd..3), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019